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Abstract
Background
Results from phase III clinical trial CheckMate 025 have established nivolumab as the stan-
dard of care for treatment of metastatic renal-cell carcinoma (mRCC) after VEGF inhibitor
failure; however, elderly patients are under-represented in the registration trial and little is
known about the activity of nivolumab in this subgroup. The purpose of the Expanded
Access Program was to provide nivolumab to patients with mRCC who had progressed
despite treatment with other agents that were considered standard of care.
Methods
Nivolumab 3 mg/kg was administered intravenously every 2 weeks to a maximum of 24
months or until progression or unacceptable toxicity. The current analysis included all
patients from the EAP Italian cohort who had received1 dose of nivolumab. Adverse
events (AEs) were monitored using Common Terminology Criteria for Adverse Events v4.0.
Results
A total of 389 patients with advanced RCC were enrolled in the Italian cohort of the EAP and
treated with nivolumab. Of these patients, 125 (32%) were at least 70 years of age and 70
(18%) were at least 75 years of age. Efficacy with nivolumab in the elderly patients was
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similar to that observed in the overall EAP population and in the CheckMate 025 trial. Safety
was comparable between the elderly patients and the overall EAP population, and was con-
sistent with what previously reported.
Conclusion
The final results suggest that elderly patients with pretreated metastatic RCC may benefit
from therapy with nivolumab.
Introduction
As a result of aging populations, the incidence of tumours in the elderly patients, including
renal cell carcinoma (RCC), continues to increase [1].
About half of the new diagnoses of renal cell carcinoma are reported in patients over 65
years of age, particularly in 25% of cases between 65 and 74 years and in another 25% of cases
over 75 years [2–3].
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb) that
selectively blocks the interaction between programmed cell death 1 (PD-1), which is expressed
on activated T cells, and PD-1 ligand 1 (PD-L1) and 2 (PD-L2), which are expressed on
immune cells and tumor cells. The PD-1 receptor is a negative regulator of T cell activity that
has been shown to be involved in immune responses of T cells in the micro-environment
tumor. The interaction of PD-1 with PD-L1 and PD-L2 ligands, expressed by the cells present-
ing the antigen and which can be expressed by the tumor cell or other cells in the tumor
micro-environment, results in inhibition of proliferation of T cell and secretion of cytokines.
Nivolumab enhances T cell responses, including anti-tumor responses, through inhibition of
PD1 binding to PD-L1 and PD-L2 ligands [4–5].
The FDA approved nivolumab in November 2015 as a treatment for patients with meta-
static renal cell carcinoma following prior antiangiogenic-based therapy based on the results of
an open-label, randomized phase III study CheckMate-025 trial, comparing nivolumab versus
everolimus.
Patients received either 3 mg/kg of IV nivolumab every 2 weeks (n = 406) or 10 mg of once
daily oral everolimus (n = 397) until disease progression or unacceptable toxicity [6].
The primary endpoint was overall survival (OS) and secondary endpoints included objec-
tive response rate (ORR), progression-free survival (PFS), quality of life (QoL) and safety.
As described in detail previously [6], Nivolumab demonstrated a better ORR (26% vs 5%).
No differences in terms of PFS was evident (4.2 months for nivolumab versus 4.5 months for
everolimus) (hazard ratio [HR], 0.85; 95% CI, 0.73–0.99; P = .0371).
Nivolumab reduced the risk of death by 26% compared with everolimus in patients with
previously treated mRCC, according to 3-year follow-up data from the phase III CheckMate-
025 study.
Median OS was 25.8 months with nivolumab compared with 19.7 months for patients
assigned to everolimus (HR, 0.74; 95% CI, 0.63–0.88; P = .0005). The 3-year OS rate with nivo-
lumab was 39% versus 30% with everolimus.
Real-World Data from an Italian EAP confirm data from the pivotal trial and suggest that
nivolumab is effective for the treatment of mRCC in routine clinical practice.
Totally, 389 pts were enrolled in the EAP across 95 Italian sites: the best overall response
rate was 17% including one complete and 66 partial responses, whereas 121 (31%) had stable
disease. With a median follow-up of 7 months (range, 1 to 16), 6-month and 9-month survival
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rates were 83% and 77%, respectively. Response and survival rates were comparable among pts
regardless age, presence of brain or bone metastases and number of prior therapies [7].
The elderly represent a consistent portion of all cancer patients, but they are often under-
represented in clinical trials [1].
Here, we report an analysis to evaluate the efficacy/safety profile of nivolumab in elderly
(70 years) or very elderly (75 years) patients enrolled in the Italian cohort of the nivolumab
Expanded Access Program.
Very elderly patients represented in the CheckMate-025 study and in the EAP, account for
8% and 19% of enrolled patients respectively.
Materials and methods
Patients
Eligible patients were 18 years of age or older, had histologic confirmation of advanced or met-
astatic renal-cell carcinoma with a clear-cell component and had received al least one prior
therapy regimens (including, but not limited to, sunitinib, sorafenib, pazopanib, axitinib, tivo-
zanib, bevacizumab, mTOR inhibitors) in the advanced or metastatic setting. Prior cytokine
therapy (eg, IL-2, IFN-y), vaccine therapy, or treatment with cytotoxics was also allowed.
All patients had a Karnofsky performance status of at least 70% at the time of study
enrollment.
Key exclusion criteria were central nervous system metastases (CNS), a condition requiring
treatment with steroids (equivalent to>10 mg of prednisone daily), prior treatment with
drugs targeting T-cell costimulation or checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-
PD-L2, anti-CD137, anti-CTLA-4), any other active malignancies or active, known, or sus-
pected autoimmune disease or a condition requiring use of systemic immunosuppressive
agents within 14 days prior to first dose. All patients signed an informed consent form.
Study design
Nivolumab was administered at a dose of 3 mg per kilogram of body weight within 60-minute
intravenous infusion every 2 weeks to a maximum of 24 months or until unacceptable toxicity,
clear disease progression, or withdrawal of informed consent. Dose modifications were not
permitted. Treatment beyond progression was allowed under protocol defined circumstances:
investigator-assessed clinical benefit and do not have rapid disease progression, severe nivolu-
mab-related AEs, stable performance status and no delay of imminent intervention to prevent
serious complications of disease progression (eg, CNS metastases). Patient provided written
informed consent prior to receiving additional nivolumab treatment. A radiographic assess-
ment/scan was performed within 6 weeks of original PD to determine whether there has been
a decrease in the tumor size or a further PD. The assessment of clinical benefit was balanced
by clinical judgment as to whether the patient was clinically deteriorating and unlikely to
receive any benefit from continued treatment with nivolumab.
The following medications were prohibited during the program (unless utilized to treat a
drug-related adverse event): immunosuppressive agents, systemic corticosteroids > 10 mg
daily prednisone equivalent and any concurrent antineoplastic therapy. Surgical resection of
lesions was permitted. Supportive care for disease-related symptoms and palliative care was
offered to all patients at the discretion of the treating physician. Live vaccines was avoided
while on study treatment. A brief course of corticosteroids for prophylaxis (eg, for contrast dye
allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity
reaction caused by a contact allergen) was permitted. Limited field palliative radiation therapy
for bone pain due to pre-existing bone metastasis was permitted.
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This analysis evaluated the safety and efficacy of nivolumab in patients with previously
treated advanced RCC in Italian patients enrolled in a worldwide expanded access program
(EAP) in elderly (70 years) or very elderly (75 years) patients enrolled in the Italian cohort
of the nivolumab Expanded Access Program who had received1 dose of nivolumab.
Adverse events (AEs) were monitored throughout the program and graded using the
National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.
Objective response rate (ORR), progression-free survival (PFS), and OS were evaluated; the
method and timing of assessments were at investigator discretion.
Study oversight
This study was approved by the institutional review board or an independent ethics committee
at each center (name of the coordinator ethics committee: “Comitato Etico Regionale per la
Sperimentazione Clinica della Regione Toscana”, ID number: CA209-99M_11098_201_2017)
and was conducted in accordance with Good Clinical Practice guidelines, as defined by the
International Conference on Harmonisation.
All the patients provided written informed consent that was based on the principles of the
Declaration of Helsinki.
Statistical analysis
Data were summarized using descriptive statistics; median and range were reported for quan-
titative variables and absolute frequencies and percentages for categorical items.
Survival curves were estimated with the Kaplan-Meier method.
Results
Patients
In total, 389 patients were enrolled in the Italian cohort of the EAP between August 2015 and
April 2016 and treated with nivolumab.
Median follow-up was 11.9 (range 1–24.7). Median nivolumab dose was 13 (range, 1–49).
Of these 389 enrolled patients, 125 (32%) were at least 70 years of age and 70 (18%) were at
least 75 years of age. Baseline patient characteristics are described in Table 1.
Median age was 65 years for all patients, and lung was the most frequent site of metastasis,
73% in all patients and patients 70 and 69% in who had 75 years. The majority of patients
had an ECOG performance status 0–1 in the three subgroups of patients and had received two
or more previous regimen of antiangiogenic therapy for advanced renal-cell carcinoma: 79%
in all patients, 72% in patients 70 years and 69% in patients 75 years.
Efficacy
The objective response rate was 23% for all patients, 27% for patients70 years of age and
28% for patients75 years of age while Stable Disease was 32%, 35% and 34% respectively.
Response outcomes are shown in Table 2 and Fig 1.
The 6-, 12- and 18% month Overall Survival rates were, respectively:
• All patients = 80.2%, 64.1% and 21.8%
• 70 years of age = 87.2%, 77.8% and 23.2%
• 75 years of age = 83.6%, 77.7% and 22.8%
Kaplan–Meier estimates of OS are shown in Fig 2.
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Safety
Treatment-related adverse events of any grade occurred in 127 of the 389 patients (33%) in the
general population, 37% in patients70 years of age and 40% in patients75 years.
Grade 3 or 4 treatment-related adverse events occurred in 27 of the 389 (7%) for all patients,
in 6 of the 125 (5%) patients70 years of age and in 3 of the 70 (4%) patients75 years.
Although there is a slightly higher incidence of toxicity regardless the grade in the elderly
and very elderly population, G3-4 Adverse Events are lower in these subgroups of patients.
The most common treatment-related AEs, of any grade, were fatigue (13%, 17% and 19%
for all patients, patients70 years and patients75 years, respectively), skin and mucosal
Table 1. Demographics and baseline patient characteristics.
Characteristics All patients
(N = 389)
70 years
(N = 125)
75 years
(N = 70)
Male, n (%) 291 (75) 94 (75) 51 (73)
Median age (range), years 65 (34–85) 75 (70–85) 77 (75–85)
ECOG PS, n (%)
0 176 (45) 47 (38) 21 (30)
1 174 (45) 67 (54) 39 (56)
2 24 (6) 7 (6) 6 (9)
NA 15 (4) 4 (3) 4 (6)
Metastatic site, n (%)
Brain 32 (8) 3 (2) 1 (1)
Bone 193 (50) 47 (38) 25 (36)
Liver 129 (33) 40 (32) 21 (30)
Lung 286 (73) 91 (73) 48 (69)
No. of prior therapies, n (%)
1 80 (21) 34 (27) 21 (30)
2 137 (35) 40 (32) 25 (36)
3 170 (44) 50 (40) 23 (33)
NA 2 (<1) 1 (1) 1 (1)
IMCD
0 62 (16) 20 (16) 12 (17)
1–2 212 (55) 72 (58) 36 (51)
> = 3 33 (8) 5 (4) 5 (7)
NA 82 (21) 28 (22) 17 (24)
NA = not available.
https://doi.org/10.1371/journal.pone.0199642.t001
Table 2. Response outcomes based on age subgroups.
Best Response All patients (%)
N = 389
70 years (%)
N = 125
75 years (%)
N = 70
CR 3 (1) 1 (1) 1 (1)
PR 87 (22) 32 (26) 19 (27)
SD 124 (32) 44 (35) 24 (34)
PD 141 (36) 38 (30) 19 (27)
NA 34 (9) 10 (8) 7 (10)
CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease.
https://doi.org/10.1371/journal.pone.0199642.t002
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toxicity (10%, 9% and 11%, respectively) and gastrointestinal toxicity (9%, 10% and 13%,
respectively)
The most frequent Grade 3 or 4 treatment-related adverse event was fatigue/asthenia 2%,
3% and 1% for all patients, patients70 years and patients75 years, respectively.
The safety outcomes for all patients, and patients70 and75 years, are shown in Table 3.
Overall, discontinuations of treatment with nivolumab in elderly and very elderly patients
were consistent with those observed in the overall population (70%, 71% and 72%, respec-
tively). Discontinuations due to treatment-related adverse events were similar in elderly
patients (8%) and the overall population (8%) and slightly more frequent in very elderly
patients (12%) (Table 4).
Discussion
The population of elderly patients in trials conducted with molecular target drugs was always
poorly represented [8]. The reasons may be various: a greater risk of adverse events and there-
fore reduced treatment tolerance, comorbidity, and reduced performance status. The available
data are derived from only partially planned analyses performed on clinical trials or extended
access programs.
Specifically, based on the results of phase III clinical trials, sunitinib, sorafenib, pazopanib,
axitinib and everolimus are able to significantly increase disease-free survival regardless of the
patient’s age and the disease status. More recently, cabozantinib and nivolumab have been
approved for the treatment of metastatic renal cell carcinoma after failure of an anti-VEGFR
therapy. In METEOR trial [9], cabozantinib is able to achieve an improvement in OS com-
pared to everolimus even in patients aged65 years, while the benefit of nivolumab appears
evident only in patients between 65 and 75 years (based on the results of CheckMate 025 [6]).
Some toxicities such as fatigue, anemia, appetite loss, dehydration, hand-foot-syndrome,
stomatitis, diarrhoea, metabolic syndrome, infections, may contraindicate systemic treatment
in elderly considered fragile patients.
Fig 1. Disease control rate based on age subgroups.
https://doi.org/10.1371/journal.pone.0199642.g001
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The analysis of Italian expanded-access program of nivolumab in mRCC confirms the effi-
cacy and safety of this agent in 389 patients in a real-world setting. Although the results pre-
sented here are limited by the nature of the expanded-access study design, these findings are
particularly valuable due to the unselected patient population. Given that the proportion of the
very elderly patients in this EAP was larger than that reported in the phase III CheckMate 025
trial (19% vs 8%), these results may provide insight into the use of nivolumab in the elderly
population.
The nivolumab safety profile described here was consistent to that observed in the overall
EAP population and in the CheckMate 025 trial6. Treatment-related AEs of any grade
occurred in 33% of global population, 37% in patients70 years of age and 40% in patients
75 years of age. These adverse events were lower compared with 79% in the CheckMate 025
trial.
Fig 2. Overall survival based on age subgroups.
https://doi.org/10.1371/journal.pone.0199642.g002
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Efficacy outcomes were consistent with previously published findings from selected popula-
tion of CheckMate 025. The ORR was 26% in CheckMate 025 trial, 23% in EAP, 27% in EAP
70 years and 28% in EAP75 years patients. In addition, disease control in the elderly popu-
lation was 58% in over 70 years and 60% in over 75 years, compared to a disease control of
59% of CheckMate 025 population.
The tolerability profile in the two subgroups has been shown to be consistent with that of
the general population. Effectiveness has also been consistent with that of the general popula-
tion of EAP and also in CheckMate 025. Although, data extracted from the extended access
program are retrospective, the results obtained suggest that elderly patients may benefit from
nivolumab as second or subsequent line of treatment.
The landscape for managing advanced RCC is rapidly changing, with a range of drugs now
approved for the treatment of this disease. Expanded-access trials are a practical way to offer a
Table 3. Treatment-related AEs in1% of all patients, elderly and very elderly patients.
Treatment-related AE All patients
(n = 389)
Any grade, n (%)
All patients
(n = 389)
Grade 3–4, n (%)
Elderly
(N = 125)
Any grade, n (%)
Elderly
(N = 125)
Grade 3–4,
n (%)
Very elderly
(n = 70)
Any grade, n (%)
Very elderly (n = 70)
Grade 3–4, n (%)
Total 127 (33) 27 (7) 46 (37) 6 (5) 28 (40) 3 (4)
General
Fatigue/asthenia 50 (13) 9 (2) 21 (17) 4 (0) 13 (19) 1 (1)
Pyrexia 12 (3) 0 (0) 5 (4) 0 (0) 2 (3) 0 (0)
Lack of appetite/anorexia 5 (1) 1 (0) 3 (2) 1 (1) 1 (1) 1 (1)
Skin and mucosal 39 (10) 2 (1) 11 (9) 0 (0) 8 (11) 0 (0)
Rash 34 (9) 2 (1) 9 (7) 0 (0) 6 (9) 0 (0)
Gastrointestinal 34 (9) 5 (1) 13 (10) 2 (2) 9 (13) 1 (1)
Diarrhea 19 (5) 3 (1) 8 (6) 1 (1) 6 (9) 1 (1)
N/V 8 (2) 2 (1) 3 (2) 1 (1) 0 (0) 0 (0)
Pain 9 (2) 0 (0) 5 (4) 0 (0) 4 (6) 0 (0)
Endocrine 13 (3) 1 (0) 5 (4) 0 (0) 2 (3) 0 (0)
Hypothyroidism 6 (2) 0 (0) 1 (1) 0 (0) 1 (1) 0 (0)
Hyperthyroidism 7 (2) 0 (0) 4 (3) 0 (0) 1 (1) 0 (0)
Autoimmune Hypophisitis 1 (0) 1 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Respiratory/pulmonary 10 (3) 3 (1) 3 (2) 0 (0) 3 (4) 0 (0)
Pneumonitis 6 (2) 1 (0) 1 (1) 0 (0) 1 (1) 0 (0)
Hematologic 11 (3) 3 (1) 2 (2) 0 (0) 1 (1) 0 (0)
Anemia 9 (2) 3 (1) 2 (2) 0 (0) 1 (1) 0 (0)
Hepatic/pancreatic 9 (2) 0 (0) 3 (2) 0 (0) 2 (3) 0 (0)
Increased transaminase 5 (1) 2 (2) 2 (3)
https://doi.org/10.1371/journal.pone.0199642.t003
Table 4. Summary of discontinuations in all patients, elderly and very elderly.
Discontinuations Patients, n (%)
N = 389
Elderly Patients, n (%)
N = 125
Patients, n (%)
N = 70
Discontinued treatment 279 (72) 87 (70) 50 (71)
Reason for discontinuation
PD 213 (76) 65 (75) 37 (74)
Death 21 (8) 5 (6) 2 (4)
AEs/serious AEs 22 (8) 7 (8) 6 (12)
Other 23 (8) 10 (11) 5 (10)
https://doi.org/10.1371/journal.pone.0199642.t004
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new agent not yet approved/commercially available to unselected patient population, to trial-
ineligible patients in a real-world setting.
Nowadays, no analysis has specifically investigated the clinical outcomes and safety profile
of nivolumab in the elderly metastatic RCC patients.
Our report has considerably extended the knowledge of the efficacy and tolerability of nivo-
lumab in unselected real-world setting and in particular in elderly.
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